Welcome to UTMB Collaborative Alzheimer's Disease and Memory Disorders Program. Cognitive impairment
and dementia including Alzheimer’s disease (AD) have posed significant social and economic burden worldwide. AD affects over 5 million Americans today, and about 360,000 of those individuals are Texans. AD is the sixth leading cause
of death in the U.S. and has an economic burden of $259 billion annually. Texas ranks fourth in the number of AD cases and second in the number of AD deaths. The objectives of our Memory Disorders Clinics at UTMB are to forestall deterioration
in dementia by early diagnosis and treatment; to identify and treat disorders other than dementia that might be contributing to the patient’s overall condition; to evaluate new therapeutic agents in the treatment of dementia; to perform
and facilitate cutting edge translational research related to AD and other neurodegenerative diseases by identifying biomarkers for early-stage AD and therapeutic intervention; to train the next generation of physicians who will provide high quality
care to those with AD and other memory disorders. We have formed multidiscipline teams from Department of Neurology, Geriatric, Radiology,
Mitchell Center for Neurodegenerative Disorders, Neuropathology, and Aging Center with goal
to provide comprehensive care from early diagnosis, treatment, and post-clinic care to those with AD and memory disorders, particularly those living in South of Texas.
Xiang Fang, M.D., Ph.D., FAAN, FANA
Professor, Neurology
John Sealy Distinguished Chair for Clinical Research in Alzheimer's Disease
Medical Director, UHC and TDC Neurology Clinic
Medical Director,
Collaborative Alzheimer's Disease & Memory Disorder Program
Department of Neurology & The Mitchell Center for Neurodegenerative Diseases
University of Texas Medical Branch (UTMB)
Galveston, TX 77555